Not provided
Not provided
Not provided
Not provided
Lack of recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A multicentre randomised controlled trial evaluating the benefit of median lobe preservation on the incidence of retrograde ejaculation during prostate enucleation by HoLEP.
The main objective of the study is to compare the incidence of retrograde ejaculation at 6 months in patients undergoing Holep surgery for prostatic adenoma according to two randomized surgical techniques: conventional surgical procedure of removal of the 3 prostatic lobes versus preservation of the median lobe.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HoLEP classic | Other | Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique). |
|
| HoLEP with median lobe preservation | Experimental | Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HoLEP with median lobe preservation | Procedure | Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum |
|
| Measure | Description | Time Frame |
|---|---|---|
| Retrograde ejaculation | Existence of retrograde ejaculation at Month 6, as evidenced by the presence of spermatozoa in the urine following sexual intercourse (as evidenced by an ECBU performed within 24 hours of intercourse) | Month 6 |
| Measure | Description | Time Frame |
|---|---|---|
| International Prostate Symtom Score (IPSS) assessment | The International Prostate Symtom Score (IPSS) is a structured and validated self-administered questionnaire that assesses the intensity and discomfort of lower urinary tract disorders. It consists of 7 questions on symptomatology with answers rated from 0 to 5 and one question on quality of life. A score of <7 is mild, a score of 8-19 is moderate and a score of >20 is severe |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Study on prostate hyperplasia
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arnaud BALDINI, MD PD | Clinique de la Sauvegarde | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique de la Sauvegarde | Lyon | 69009 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011470 | Prostatic Hyperplasia |
| ID | Term |
|---|---|
| D011469 | Prostatic Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
A prospective randomised multicentre single-blind comparative study of two parallel groups of patients scheduled for HoLEP prostate resection:
Group 1 Conventional HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
Group 2 Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum Each patient will be evaluated five times during the study (D0, M1, M3, M6, M12) The total duration of the study is 2 years (1 year of recruitment and 1 year of follow-up).
Not provided
Not provided
The patient does not know which type of surgery is used
| HoLEP classic | Procedure | Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique). |
|
| Month 1 |
| International Prostate Symtom Score (IPSS) assessment | The International Prostate Symtom Score (IPSS) is a structured and validated self-administered questionnaire that assesses the intensity and discomfort of lower urinary tract disorders. It consists of 7 questions on symptomatology with answers rated from 0 to 5 and one question on quality of life. A score of <7 is mild, a score of 8-19 is moderate and a score of >20 is severe | Month 3 |
| International Prostate Symtom Score (IPSS) assessment | The International Prostate Symtom Score (IPSS) is a structured and validated self-administered questionnaire that assesses the intensity and discomfort of lower urinary tract disorders. It consists of 7 questions on symptomatology with answers rated from 0 to 5 and one question on quality of life. A score of <7 is mild, a score of 8-19 is moderate and a score of >20 is severe | Month 6 |
| International Prostate Symtom Score (IPSS) assessment | The International Prostate Symtom Score (IPSS) is a structured and validated self-administered questionnaire that assesses the intensity and discomfort of lower urinary tract disorders. It consists of 7 questions on symptomatology with answers rated from 0 to 5 and one question on quality of life. A score of <7 is mild, a score of 8-19 is moderate and a score of >20 is severe | Month 12 |
| Men Sexual Health Questionnaire (MSHQ) score assessment | The Men Sexual Health Questionnaire (MSHQ) assesses a patient's ability to have sex. It consists of 25 questions that explore the ability to have erections, the quality of ejaculations and the satisfaction felt during intercourse and sexual desire. The total score (16 to 125 points maximum) is broken down into 6 sub-scores that explore erection (0 to 15 points), discomfort with erection problems (1 to 5 points), ejaculation (1 to 35 points), discomfort with ejaculation problems (1 to 5 points), satisfaction (6 to 30 points), sexual activity and desire (7 to 35 points) | Month 3 |
| Men Sexual Health Questionnaire (MSHQ) score assessment | The Men Sexual Health Questionnaire (MSHQ) assesses a patient's ability to have sex. It consists of 25 questions that explore the ability to have erections, the quality of ejaculations and the satisfaction felt during intercourse and sexual desire. The total score (16 to 125 points maximum) is broken down into 6 sub-scores that explore erection (0 to 15 points), discomfort with erection problems (1 to 5 points), ejaculation (1 to 35 points), discomfort with ejaculation problems (1 to 5 points), satisfaction (6 to 30 points), sexual activity and desire (7 to 35 points) | Month 6 |
| Men Sexual Health Questionnaire (MSHQ) score assessment | The Men Sexual Health Questionnaire (MSHQ) assesses a patient's ability to have sex. It consists of 25 questions that explore the ability to have erections, the quality of ejaculations and the satisfaction felt during intercourse and sexual desire. The total score (16 to 125 points maximum) is broken down into 6 sub-scores that explore erection (0 to 15 points), discomfort with erection problems (1 to 5 points), ejaculation (1 to 35 points), discomfort with ejaculation problems (1 to 5 points), satisfaction (6 to 30 points), sexual activity and desire (7 to 35 points) | Month 12 |
| International Index of Erectil Function (IIEF-5) score assessment | The IIEF-5 (International Index of Erectile Function) questionnaire consists of 5 questions that assess erectile function over the past 6 months. Severe erectile dysfunction corresponds to a score of 5-10, moderate erectile dysfunction to a score of 11-15 and mild erectile dysfunction to a score of 16-20. A score of 21 to 25 corresponds to normal erectile function and scores between 1 and 4 are not interpretable. | Month 3 |
| International Index of Erectil Function (IIEF-5) score assessment | The IIEF-5 (International Index of Erectile Function) questionnaire consists of 5 questions that assess erectile function over the past 6 months. Severe erectile dysfunction corresponds to a score of 5-10, moderate erectile dysfunction to a score of 11-15 and mild erectile dysfunction to a score of 16-20. A score of 21 to 25 corresponds to normal erectile function and scores between 1 and 4 are not interpretable. | Month 6 |
| International Index of Erectil Function (IIEF-5) score assessment | The IIEF-5 (International Index of Erectile Function) questionnaire consists of 5 questions that assess erectile function over the past 6 months. Severe erectile dysfunction corresponds to a score of 5-10, moderate erectile dysfunction to a score of 11-15 and mild erectile dysfunction to a score of 16-20. A score of 21 to 25 corresponds to normal erectile function and scores between 1 and 4 are not interpretable. | Month 12 |
| Urine flow (Qmax) measurement | Assessment of urine flow (Qmax) by ultrasound | Month 1 |
| Urine flow (Qmax) measurement | Assessment of urine flow (Qmax) by ultrasound | Month 3 |
| Urine flow (Qmax) measurement | Assessment of urine flow (Qmax) by ultrasound | Month 6 |
| Urine flow (Qmax) measurement | Assessment of urine flow (Qmax) by ultrasound | Month 12 |
| Adverse events related to the procedure | Presence of urinary incontinence and occurrence of adverse events related to the procedure | Month 12 |
| Assessment of resected volume / total volume | Assessment of resected volume / total volume assessed by ultrasound | Month 12 |
| D052801 |
| Male Urogenital Diseases |